Study of ublituximab for walking and movement in multiple sclerosis
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests if ublituximab can improve walking and other motor skills in people with active relapsing MS. You must be able to walk at least 25 feet and stand 30 seconds on your own.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 55 years old
- Have active relapsing MS (not primary progressive or other forms)
- Can walk at least 25 feet with or without a cane or walker
- Can stand on your own for at least 30 seconds
- Not be pregnant and agree to use effective birth control if you can become pregnant
- No other major neurological or psychiatric conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests ublituximab (Briumvi), a treatment given as an infusion, for people recently diagnosed with relapsing MS. The goal is to see if starting this treatment early helps control MS better.
This study uses a special eye scan (OCT) to see how well the MS medication ublituximab works. It compares people starting ublituximab to those on other stable MS treatments, to find better ways to measure treatment success.
This trial tests an oral drug called remibrutinib to see if it can help people with relapsing or progressive multiple sclerosis. It uses brain scans (MRI) to track how well the drug works.
This study looks at how a new pill for multiple sclerosis (MS) affects brain inflammation and immune cells. It may help people who are already taking an MS medication but want to switch to a different one.
This Phase 3 trial tests the safety and effectiveness of a modified treatment plan using ublituximab for relapsing multiple sclerosis. It also studies how the drug behaves in the body and aims to improve disease control while monitoring side effects.
This study tests an investigational medication called ublituximab (an infusion) for people with a rare autoimmune muscle disease called IMNM. It aims to reduce muscle weakness and damage by targeting specific immune cells (B cells). To join, you need a recent diagnosis (within 1 year), specific antibodies, and be on limited other medications.
Hear when a new Multiple Sclerosis (MS) - Relapsing-remitting trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.